This is a non-core endpoint: only basic statistics are computed.
See its core counterpart C3_SECONDARY_NAS_EXALLC for full statistics.
Secondary malignant neoplasm of other and unspecified sites
C3_SECONDARY_NAS
No definition available.
Endpoint definition
↥
FinnGen phenotype data
429209 individuals
Apply sex-specific rule None
429209
Check conditions None
429209
Check pre-conditions, main-only, mode, registry filters
Cause of death: ICD-10
C79
Cause of death: ICD-8
198
Cancer registry: Topography ICD-O-3
C79
Cancer registry: Morphology ICD-O-3
ANY
Cancer registry: Behaviour codes
3
2 out of 7 registries used, show all original rules.
318
Check minimum number of events None
318
Include endpoints None
318
Remove individuals based on genotype QC
307
C3_SECONDARY_NAS
Control definitions
Controls for this endpoint are individuals that are not cases.
Extra metadata
Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF9
Show upset plot detailing case counts by codes
Or the full data table
Similar endpoints
↥List of similar endpoints to
Secondary malignant neoplasm of other and unspecified sites
based on the number of shared cases.
Broader endpoints:
- Secondary malignant neoplasm of other and unspecified sites (controls excluding all cancers)
- Secondary uncertain malignant neoplasm (controls excluding all cancers)
- Secondary uncertain malignant neoplasm
- Any death
- Malignant neoplasm (controls excluding all cancers)
Narrower endpoints:
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 307 | 120 | 187 |
| Unadjusted prevalence (%) | 0.07 | 0.05 | 0.10 |
| Mean age at first event (years) | 71.07 | 66.92 | 73.74 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: C3_SECONDARY_NAS – Secondary malignant neoplasm of other and unspecified sites
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Secondary malignant neoplasm of other and unspecified sites
↥Endpoint not on priority list, no data to show.